Medicare Pass-Through Payment System Needs Revision, MedPAC Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Anti-emetics illustrate the problem with the policy of providing separate payments for drugs over $50, MedPAC says. CMS is urged to use the pass-through process for all categories. MedPAC endorses CMS' proposed reimbursement change for Aranesp and Epogen in end-stage renal disease.
You may also be interested in...
Amgen EPO Claims Monitoring To Include Dosing Levels – CMS Draft Policy
Proposed revision would replace current policy of targeting physicians whose patients have average hematocrit levels over 37.5%. New policy would review erythropoietin claims with high hematocrit/hemoglobin levels and high doses.
Pink Sheet Podcast: Relyvrio And Public Promises, Allergy Biomarker Adcomms, PMDA In The USA
Pink Sheet reporters and editor discuss the implications of Amylyx following through on its pledge to remove Relyvrio from the market after its trial failed, an FDA idea to bring potential biomarkers for promising allergy and asthma treatments to advisory committees, and Japan’s PMDA opening an office in Washington D.C.
Pink Sheet Podcast: Mifepristone And Misinformation At SCOTUS, Understanding US FDA’s ODAC
Pink Sheet reporters and editor discuss the upcoming US Supreme Court arguments on mifepristone access, the SCOTUS reaction to the fight against misinformation, and the FDA’s Oncologic Drugs Advisory Committee going against three negative product reviews.